Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system

SARS-CoV-2 binds to ACE2 receptors, expressed within the lungs. Risk factors for hospitalization include hypertension, diabetes, ischaemic heart disease and obesity–conditions linked by the presence of endothelial pathology. Viral infection in this setting causes increased conversion of circulating Factor XII to its active form (FXIIa). This is the first step in the contact-kinin pathway, leading to synchronous activation of the intrinsic coagulation cascade and the plasma Kallikrein-Kinin system, resulting in clotting and inflammatory lung disease. Temporal trends are evident from blood results of hospitalized patients. In the first week of symptoms the activated partial thromboplastin time (APTT) is prolonged. This can occur when clotting factors are consumed as part of the contact (intrinsic) pathway. Platelet counts initially fall, reflecting their consumption in coagulation. Lymphopenia occurs after approximately 1 week, reflecting the emergence of a lymphocytic pneumonitis [COVID-19 acute respiratory distress syndrome (ARDS)]. Intrinsic coagulation also induces the contact-kinin pathway of inflammation. A major product of this pathway, bradykinin causes oedema with ground glass opacities (GGO) on imaging in early COVID-19. Bradykinin also causes release of the pleiotrophic cytokine IL-6, which causes lymphocyte recruitment. Thromobosis and lymphocytic pneumonitis are hallmark features of COVID-19 ARDS. In this review we examine the literature with particular reference to the contact-kinin pathway. Measurements of platelets, lymphocytes and APTT should be undertaken in severe infections to stratify for risk of developing ARDS.

[1]  A. Jannot,et al.  Fibrin monomers evaluation during hospitalization for COVID-19 is a predictive marker of in-hospital mortality , 2023, Frontiers in Cardiovascular Medicine.

[2]  L. Esserman,et al.  Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial , 2023, eClinicalMedicine.

[3]  I. Martín-Loeches,et al.  Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19 , 2023, Research and Practice in Thrombosis and Haemostasis.

[4]  C. Samama,et al.  Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation , 2023, Archives of Cardiovascular Diseases.

[5]  J. Hansen,et al.  C1 inhibitor deficiency enhances contact pathway mediated activation of coagulation and venous thrombosis. , 2023, Blood.

[6]  X. Solanich,et al.  Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial , 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Karsdal,et al.  The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling , 2022, eBioMedicine.

[8]  R. D. De Jongh,et al.  Coagulation parameters predict COVID-19-related thrombosis in a neural network with a positive predictive value of 98% , 2022, Frontiers in Immunology.

[9]  C. Agrati,et al.  SARS-CoV-2 Infection of Airway Epithelium Triggers Pulmonary Endothelial Cell Activation and Senescence Associated with Type I IFN Production , 2022, Cells.

[10]  Shaima Hussain Alnajjad,et al.  Implications for COVID-19 , 2022, International journal of health sciences.

[11]  F. Llopis,et al.  Exceptional treatment of COVID-19 pneumonia with icatibant. , 2022, Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias.

[12]  J. Bernstein,et al.  Inhibition of Prekallikrein for Hereditary Angioedema. , 2022, The New England journal of medicine.

[13]  I. De Meester,et al.  Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients , 2022, Clinica Chimica Acta.

[14]  A. Egesten,et al.  Comorbidities in hereditary angioedema—A population‐based cohort study , 2022, Clinical and translational allergy.

[15]  B. Stieltjes,et al.  Automated lung vessel segmentation reveals blood vessel volume redistribution in viral pneumonia. , 2022, European journal of radiology.

[16]  J. Barberà,et al.  Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge , 2022, Respiratory Research.

[17]  James Batchelor,et al.  Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital , 2022, BMJ Open.

[18]  S. Nagashima,et al.  COVID-19 and Lung Mast Cells: The Kallikrein–Kinin Activation Pathway , 2022, International journal of molecular sciences.

[19]  Z. Prohászka,et al.  Associations between the von Willebrand Factor—ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality , 2022, Thrombosis and haemostasis.

[20]  N. Hacohen,et al.  Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19 , 2021, American journal of respiratory and critical care medicine.

[21]  K. Preissner,et al.  Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19 , 2021, Blood Advances.

[22]  Dipti K. Pawaskar,et al.  A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab , 2021, Clinical and translational science.

[23]  M. Netea,et al.  Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19 , 2021, Thrombosis Research.

[24]  M. Garg,et al.  Association of Inflammatory Markers with COVID-19 Outcome among Hospitalized Patients: Experience from a Tertiary Healthcare Center in Western India. , 2021, Maedica.

[25]  A. Jannot,et al.  Daily Monitoring of D-Dimer Allows Outcomes Prediction in COVID-19 , 2021, TH Open.

[26]  T. Molnár,et al.  Plasma Fibrinogen Independently Predicts Hypofibrinolysis in Severe COVID-19 , 2021, Metabolites.

[27]  A. Egli,et al.  Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study , 2021, Frontiers in Immunology.

[28]  M. Guazzi,et al.  Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study , 2021, International Journal of Cardiology.

[29]  A. Pakhare,et al.  Adequate Antithrombin III Level Predicts Survival in Severe COVID-19 Pneumonia , 2021, Cureus.

[30]  M. Rava,et al.  Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality? , 2021, Frontiers in Medicine.

[31]  Reamer L. Bushardt,et al.  Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID‐19: A propensity score‐matched analysis , 2021, Journal of Thrombosis and Haemostasis.

[32]  A. V. Sorokina,et al.  Pathological Features in 100 Deceased Patients With COVID-19 in Correlation With Clinical and Laboratory Data , 2021, Pathology & Oncology Research.

[33]  S. Thiel,et al.  Protease inhibitor plasma concentrations associate with COVID-19 infection , 2021, Oxford open immunology.

[34]  G. Lippi,et al.  Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature , 2021, Seminars in Thrombosis and Hemostasis.

[35]  M. Landray,et al.  Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[36]  Liang Chen,et al.  Dynamic changes in coagulation parameters and correlation with disease severity and mortality in patients with COVID-19 , 2021, Aging.

[37]  Jiasheng Xu,et al.  Dynamic Changes in Coagulation Function in Patients With Pneumonia Under Admission and Non-admission Treatment , 2021, Frontiers in Medicine.

[38]  Ramazan Sabırlı,et al.  Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study , 2021, Life Sciences.

[39]  Safae Abu Yousef,et al.  Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study , 2021, Rheumatology International.

[40]  L. Bonomo,et al.  COVID-19 pneumonia: current evidence of chest imaging features, evolution and prognosis , 2021, Chinese Journal of Academic Radiology.

[41]  Brad J. Wood,et al.  Remarkable vessel enlargement within lung consolidation in COVID-19 compared to AH1N1 pneumonia: A retrospective study in Italy , 2021, Heliyon.

[42]  L. Samavati,et al.  Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review , 2021, RMD Open.

[43]  P. Manunta,et al.  Role of blood pressure dysregulation on kidney and mortality outcomes in COVID-19. Kidney, blood pressure and mortality in SARS-CoV-2 infection , 2021, Journal of Nephrology.

[44]  C. Agrati,et al.  Elevated P-Selectin in Severe Covid-19: Considerations for Therapeutic Options , 2021, Mediterranean journal of hematology and infectious diseases.

[45]  M. Gawaz,et al.  Severe SARS-CoV-2 Infection Inhibits Fibrinolysis Leading to Changes in Viscoelastic Properties of Blood Clot: A Descriptive Study of Fibrinolysis in COVID-19 , 2021, Thrombosis and Haemostasis.

[46]  B. Nilsson,et al.  The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System , 2021, Frontiers in Immunology.

[47]  C. Fu,et al.  The effect of coagulation factors in 2019 novel coronavirus patients , 2021, Medicine.

[48]  J. Pedrosa,et al.  Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia , 2021, Frontiers in Immunology.

[49]  Guangwei Luo,et al.  The Inflammatory Factors Associated with Disease Severity to Predict COVID-19 Progression , 2021, The Journal of Immunology.

[50]  L. Velloso,et al.  Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19 , 2021, Viruses.

[51]  Achmet Ali,et al.  Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study , 2021, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[52]  Ying Zhu,et al.  Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19 , 2021, BMC Infectious Diseases.

[53]  F. Pène,et al.  Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality , 2021, Angiogenesis.

[54]  J. Haas,et al.  Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells , 2021, Circulation.

[55]  Ming Chen,et al.  Association of coagulation disturbances with severity of COVID-19: a longitudinal study , 2021, Hematology.

[56]  Evi X. Stavrou,et al.  Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation , 2020, bioRxiv.

[57]  G. D'offizi,et al.  COVID-19 disease—Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study , 2020, PloS one.

[58]  B. Mégarbane,et al.  von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate‐to‐severe COVID‐19 patients , 2020, British journal of haematology.

[59]  N. Mackman,et al.  Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19 , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[60]  Xinmin Liu,et al.  Coagulopathy in patients with COVID-19: a systematic review and meta-analysis , 2020, Aging.

[61]  G. Grasselli,et al.  The ADAMTS13‐von Willebrand factor axis in COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[62]  D. Jiménez,et al.  Incidence of venous thromboembolism and bleeding among hospitalized patients with COVID-19: a systematic review and meta-analysis , 2020, Chest.

[63]  T. Ortel,et al.  Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis , 2020, Journal of thrombosis and haemostasis : JTH.

[64]  A. Pesenti,et al.  Complement activation and endothelial perturbation parallel COVID-19 severity and activity , 2020, Journal of Autoimmunity.

[65]  William H. Yang,et al.  Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. , 2020, The Journal of allergy and clinical immunology.

[66]  M. Serteser,et al.  Proteins associated with neutrophil degranulation are upregulated in nasopharyngeal swabs from SARS-CoV-2 patients , 2020, PloS one.

[67]  N. Barabutis Unfolded protein response in the COVID-19 context , 2020, Aging and Health Research.

[68]  M. Aepfelbacher,et al.  Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.

[69]  L. V. Van Pelt,et al.  A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study , 2020, medRxiv.

[70]  P. Moceri,et al.  High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019 , 2020, Journal of the American Heart Association.

[71]  M. Zuin,et al.  Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis. , 2020, European Journal of Internal Medicine.

[72]  J. Abisheganaden,et al.  Temporal changes of haematological and radiological findings of the COVID-19 infection—a review of literature , 2020, BMC Pulmonary Medicine.

[73]  P. Saldiva,et al.  SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology , 2020, The Journal of experimental medicine.

[74]  M. Fasshauer,et al.  Circulating cell adhesion molecules in metabolically healthy obesity , 2020, International Journal of Obesity.

[75]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[76]  M. Thaysen‐Andersen,et al.  Structural and functional diversity of neutrophil glycosylation in innate immunity and related disorders. , 2020, Molecular aspects of medicine.

[77]  Stephan Moser,et al.  Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System , 2020, Frontiers in Immunology.

[78]  E. Mylonakis,et al.  Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis , 2020, Clinical Radiology.

[79]  H. Billett,et al.  Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA network open.

[80]  M. Netea,et al.  Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19 , 2020, JAMA network open.

[81]  C. Gazzaruso,et al.  Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity , 2020, Nutrition, Metabolism and Cardiovascular Diseases.

[82]  P. D. de Groot,et al.  Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. , 2020, Respiratory medicine.

[83]  Junyu Lu,et al.  Coagulation dysfunction is associated with severity of COVID‐19: A meta‐analysis , 2020, Journal of Medical Virology.

[84]  Wen Zeng,et al.  Dynamic Interleukin-6 Level Changes as a Prognostic Indicator in Patients With COVID-19 , 2020, Frontiers in Pharmacology.

[85]  Liqing Cheng,et al.  Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis , 2020, Aging.

[86]  B. Mégarbane,et al.  Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? , 2020, Thrombosis Research.

[87]  Jianfang Liu,et al.  Time-dependent changes in the clinical characteristics and prognosis of hospitalized COVID-19 patients in Wuhan, China: A retrospective study , 2020, Clinica Chimica Acta.

[88]  S. Tavangar,et al.  Pathologic features of COVID-19: A concise review , 2020, Pathology - Research and Practice.

[89]  C. D. Dela Cruz,et al.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.

[90]  P. Georgius,et al.  COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease , 2020, Medical Hypotheses.

[91]  E. Messas,et al.  Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients , 2020, Angiogenesis.

[92]  Fen Li,et al.  Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross‐sectional study , 2020, Journal of medical virology.

[93]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[94]  W. Liang,et al.  Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China , 2020, Journal of Allergy and Clinical Immunology.

[95]  Xiaosheng Wang,et al.  Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues , 2020, Infectious Diseases of Poverty.

[96]  T. de Giacomo,et al.  Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen , 2020, Virchows Archiv.

[97]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[98]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[99]  Mario Plebani,et al.  Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis , 2020, Clinical chemistry and laboratory medicine.

[100]  A. Laghi,et al.  Chest CT Features of COVID-19 in Rome, Italy , 2020, Radiology.

[101]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[102]  T. West,et al.  Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.

[103]  D. Sin,et al.  ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 , 2020, European Respiratory Journal.

[104]  Tian Huang,et al.  COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis , 2020, Journal of medical virology.

[105]  Rui Ji,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[106]  Haibo Xu,et al.  Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer , 2020, Journal of Thoracic Oncology.

[107]  R. Liu,et al.  Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.

[108]  Nabil Al-Ama,et al.  Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications , 2019, The Journal of international medical research.

[109]  M. S. Sajib,et al.  Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology , 2019, Cells.

[110]  William H. Yang,et al.  Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial , 2018, JAMA.

[111]  M. Bader,et al.  Kinin B1 receptors as a therapeutic target for inflammation , 2018, Expert opinion on therapeutic targets.

[112]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[113]  T. Renné,et al.  The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. , 2017, Biochimica et biophysica acta. Molecular cell research.

[114]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[115]  A. Schmaier,et al.  The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities , 2016, Journal of thrombosis and haemostasis : JTH.

[116]  W. Lumry,et al.  Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3 , 2015, International Archives of Allergy and Immunology.

[117]  T. Mccauley,et al.  Pharmacokinetics of single and repeat doses of icatibant , 2015, Clinical pharmacology in drug development.

[118]  R. Santos,et al.  Angiotensin-(1-7): beyond the cardio-renal actions. , 2013, Clinical science.

[119]  A. de la Sierra,et al.  Abnormalities of vascular function in resistant hypertension , 2012, Blood pressure.

[120]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[121]  W. Lumry,et al.  EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[122]  T. Ortel,et al.  Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[123]  A. Christensson,et al.  Neutrophil-Derived Proteinase 3 Induces Kallikrein-Independent Release of a Novel Vasoactive Kinin12 , 2009, The Journal of Immunology.

[124]  Yixue Xue,et al.  Bradykinin-induced blood–tumor barrier opening is mediated by tumor necrosis factor-α , 2009, Neuroscience Letters.

[125]  Ç. Yenisey,et al.  Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation , 2008, Journal of Thrombosis and Thrombolysis.

[126]  M. Willingham,et al.  Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[127]  F. Schmidt Meta-Analysis , 2008 .

[128]  T. Baglin,et al.  Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls , 2006, British journal of haematology.

[129]  R. D'Agostino,et al.  Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. , 2006, Diabetes.

[130]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[131]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[132]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[133]  J. Manson,et al.  Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. , 2004, JAMA.

[134]  J. Sung,et al.  Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis , 2003, BMJ : British Medical Journal.

[135]  G. Lip,et al.  Von Willebrand Factor, Soluble P-Selectin, and Target Organ Damage in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) , 2002, Hypertension.

[136]  S. Tanase,et al.  Release of a new vascular permeability enhancing peptide from kininogens by human neutrophil elastase. , 2002, Biochemical and biophysical research communications.

[137]  H. Arnesen,et al.  Increased levels of markers of vascular inflammation in patients with coronary heart disease , 2002, Scandinavian journal of clinical and laboratory investigation.

[138]  G. Lip,et al.  A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. , 2001, American journal of hypertension.

[139]  H. Granger,et al.  B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF‐2 effects , 1998, British journal of pharmacology.

[140]  W. Knaus,et al.  Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. , 1997, JAMA.

[141]  K. Chung,et al.  Bradykinin–evoked sensitization of airway sensory nerves: A mechanism for ACE–inhibitor cough , 1996, Nature Medicine.

[142]  D. Ward,et al.  Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. , 1994, Genomics.

[143]  J. Imbs,et al.  Cough and ACE inhibitors , 1993, The Lancet.

[144]  M. FitzGerald,et al.  Captopril and lymphocytic alveolitis. , 1989, BMJ.

[145]  K. Siddiqui,et al.  Incidence of lupus anticoagulant in hospitalized covid-19 patients. , 2021, American journal of blood research.

[146]  Recovery Collaborative Group Lopinavir-Ritonavir in Hospitalised Patients with COVID-19: Preliminary Report from a Randomised, Controlled, Open-Label, Platform Trial , 2020, SSRN Electronic Journal.

[147]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[148]  藤倉雄二,et al.  わが国における成人市中肺炎の原因微生物の変遷(Meta‐analysis and systematic review) , 2017 .

[149]  Maja O’Connor LONGITUDINAL STUDY , 2013 .

[150]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[151]  T. Zelinka,et al.  Biochemical markers of endothelial dysfunction in patients with endocrine and essential hypertension. , 2006, Physiological research.

[152]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[153]  P. Allhoff,et al.  The Framingham Offspring Study , 1991 .

[154]  M. F. Parry,et al.  A Retrospective Analysis , 1990 .

[155]  E. Glaser The randomized clinical trial. , 1972, The New England journal of medicine.